MEA Mycoplasma Testing Market Report

MEA Mycoplasma Testing Market Size

The size of the mycoplasma testing market in the Middle East and Africa is predicted to be worth USD 152.80 Million by 2033 and USD 74.99 Million in 2024, growing at a CAGR of 8.23% from 2024 to 2033.

Mycoplasma Testing Market refers to diagnostic procedures employed for the detection of Mycoplasma species, particularly Mycoplasma pneumoniae and Ureaplasma urealyticum, which are responsible for a range of respiratory and urogenital infections. These microorganisms, lacking cell walls, are inherently resistant to several common antibiotics such as beta-lactams, making early and accurate detection critical for effective treatment planning. The market encompasses a variety of testing methodologies including serological assays, polymerase chain reaction (PCR), culture-based techniques, and rapid antigen tests, all aimed at improving diagnostic accuracy and patient outcomes.

In recent years, rising awareness around sexually transmitted infections (STIs) and community-acquired pneumonia has significantly influenced healthcare strategies in the region. According to the World Health Organization (WHO), respiratory tract infections account for over 20% of outpatient visits in sub-Saharan Africa, with Mycoplasma pneumoniae being a notable causative agent among school-going children and young adults.

MARKET DRIVERS

Rising Incidence of Respiratory Infections Across the Region

The increasing prevalence of respiratory infections, particularly those caused by Mycoplasma pneumoniae is one of the primary drivers influencing the growth of the MEA Mycoplasma Testing Market. This pathogen is a leading cause of atypical pneumonia and upper respiratory tract infections, especially in densely populated urban centers and educational institutions where transmission rates are high. According to the Eastern Mediterranean Public Health Network (EMPHNET), mycoplasma-associated pneumonia accounts for nearly 10–15% of all community-acquired pneumonia (CAP) cases in countries like Saudi Arabia, Egypt, and Iran, with spikes observed during seasonal transitions.

Moreover, the growing geriatric population in Gulf Cooperation Council (GCC) countries—projected to reach 10% of the total population by 2030 as per the United Nations Department of Economic and Social Affairs—has heightened vulnerability to respiratory illnesses, thereby increasing the demand for rapid and accurate diagnostic methods. The rise in hospitalizations due to prolonged symptoms and complications from untreated mycoplasma infections has further stregthened the need for advanced molecular diagnostics, especially PCR-based platforms, which offer higher sensitivity and faster turnaround times.

Increasing Awareness and Government Initiatives in STI Screening Programs

The growing emphasis on sexual and reproductive health, particularly through government-backed screening programs targeting sexually transmitted infections (STIs), is another significant driver of the MEA Mycoplasma Testing Market. Mycoplasma genitalium and Ureaplasma urealyticum have emerged as key contributors to non-chlamydial, non-gonococcal urethritis and other reproductive complications, including infertility and adverse pregnancy outcomes. As per the World Health Organization (WHO), over 1 million new STI cases are acquired daily worldwide, with the African region bearing a disproportionately high burden.

In response, several governments in the MEA region have intensified public health campaigns and expanded access to STI diagnostic services. Similarly, as per the Saudi Center for Disease Prevention and Control, there is a 34% increase in STI screenings between 2021 and 2023, with a specific focus on mycoplasma strains due to their association with antibiotic resistance. Besides, nongovernmental organizations such as the African Union’s Partnership for Accelerating COVID-19 Testing (PACT) initiative have indirectly supported broader STI diagnostic capacity building, thereby creating an enabling environment for the expansion of mycoplasma-specific testing protocols.

MARKET RESTRAINTS

Limited Healthcare Infrastructure and Diagnostic Accessibility in Sub-Saharan Africa

The inadequate healthcare infrastructure across many sub-Saharan African nations, which severely limits access to advanced diagnostic services, is a major restraint impeding the growth of the MEA Mycoplasma Testing Market. Countries such as Nigeria, Ethiopia, and Tanzania continue to face challenges related to underfunded public health systems, insufficient laboratory facilities, and a shortage of trained medical personnel. According to the World Bank, in 2022, less than 30% of the population in these countries had reliable access to basic diagnostic services, let alone specialized tests for pathogens like Mycoplasma .

This infrastructural deficit directly affects the ability to conduct timely and accurate mycoplasma testing, especially in rural areas where transportation and storage of clinical samples pose logistical difficulties. The lack of standardized diagnostic protocols and poor integration of digital health records also contribute to delayed or missed diagnoses. Without substantial investment in laboratory modernization and workforce development, the potential for market expansion remains constrained despite rising disease prevalence.

High Cost of Advanced Diagnostic Technologies and Reagents

The high cost associated with advanced diagnostic technologies, including real-time PCR machines, nucleic acid extraction kits, and proprietary reagents, is another critical challenge facing the MEA Mycoplasma Testing Market. These expenses create a significant barrier for both public and private healthcare providers, particularly in low-income economies within the region.

Apart from these, recurrent costs for consumables and maintenance further strain already limited healthcare budgets. Many diagnostic centers in the region rely on international donor funding or fragmented procurement mechanisms, which often result in inconsistent supply chains and price volatility. As per a 2023 report by the Global Fund, nearly 40% of diagnostic labs in West Africa experienced stockouts of essential testing kits due to financial constraints and supplier delays. Consequently, the adoption of sophisticated mycoplasma testing solutions remains uneven across the MEA region, limiting the market's potential for widespread penetration and equitable healthcare delivery.

MARKET OPPORTUNITIES

Expansion of Point-of-Care Testing in Remote Areas

The growing deployment of point-of-care (POC) diagnostic technologies, particularly in remote and underserved regions is a significant opportunity for the MEA Mycoplasma Testing Market. Traditional centralized laboratory testing faces logistical hurdles in areas with poor transport networks and limited electricity access. POC devices, such as rapid antigen tests and portable PCR systems, offer a viable alternative by delivering quick, on-site results without the need for complex infrastructure.

According to the Foundation for Innovative New Diagnostics (FIND), in 2023, the use of mobile diagnostic units equipped with POC capabilities increased by 28% across East and West Africa, driven by initiatives from global health organizations and local governments. With advancements in microfluidics and biosensor technologies, POC testing is expected to become more affordable and widely adopted.

Integration of Artificial Intelligence in Diagnostic Interpretation

The integration of artificial intelligence (AI) into diagnostic workflows presents a transformative opportunity for the MEA Mycoplasma Testing Market. AI-driven algorithms can enhance the accuracy of test interpretation, reduce human error, and streamline data management in resource-constrained environments. Several tech-health collaborations in the MEA region are beginning to leverage machine learning for pattern recognition in infectious diseases. Similarly, South Africa’s National Health Laboratory Service (NHLS) piloted an AI-based platform that correlates clinical symptoms with lab results to improve early diagnosis of atypical pneumonia cases.Furthermore, cloud-connected AI systems allow for real-time surveillance and outbreak prediction, supporting public health decision-making.

MARKET CHALLENGES

Lack of Standardized Testing Protocols Across Countries

The absence of standardized testing protocols across different countries, leading to inconsistencies in diagnostic quality and reporting, is one of the most pressing challenges in the MEA Mycoplasma Testing Market. Unlike regions such as Europe or North America, where regulatory bodies like the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) provide unified guidelines, the MEA region lacks a cohesive framework for mycoplasma detection.

According to the African Society for Laboratory Medicine (ASLM), in 2023, only 12 out of 54 African countries had established national guidelines for mycoplasma testing, resulting in varied methodologies, reagent choices, and interpretation criteria. For example, while some laboratories in the GCC states employ real-time PCR as the gold standard, others in North Africa still rely heavily on conventional serology, which is less sensitive and prone to cross-reactivity.

This heterogeneity complicates inter-country comparisons of disease prevalence and hampers regional surveillance efforts. Moreover, it poses challenges for multinational pharmaceutical and diagnostic companies seeking to introduce new testing products in the MEA market, as they must navigate disparate regulatory landscapes. The absence of harmonized standards also affects training and proficiency testing for laboratory personnel, further undermining diagnostic reliability and impeding market growth.

Antimicrobial Resistance and Its Impact on Diagnostic Demand

Antimicrobial resistance (AMR) poses a significant challenge to the MEA Mycoplasma Testing Market, as Mycoplasma pneumoniae and related species exhibit increasing resistance to commonly used antibiotics, particularly macrolides. Unlike bacteria with cell walls, mycoplasmas are inherently resistant to beta-lactam antibiotics, necessitating precise identification and susceptibility profiling to guide appropriate therapy. However, according to the World Health Organization (WHO), in 2023, macrolide-resistant Mycoplasma pneumoniae strains accounted for over 40% of isolates in certain parts of the Middle East, notably Lebanon and Jordan.

This growing resistance trend underscores the urgent need for accurate and rapid diagnostics to avoid empirical prescribing and reduce treatment failures. Yet, the availability of antimicrobial susceptibility testing (AST) for mycoplasmas remains limited across much of the MEA region due to technical complexities and resource constraints. As reported by the Eastern Mediterranean Antimicrobial Resistance Surveillance Network (EMARSN), fewer than 20% of microbiology labs in the Middle East routinely perform AST for mycoplasma species.

Without widespread access to resistance testing, clinicians often resort to second-line antibiotics, which may be costlier and less accessible. This dynamic not only exacerbates patient outcomes but also diminishes the perceived value of mycoplasma testing, thereby slowing market adoption despite rising disease incidence.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

The kits and reagents segment led the MEA Mycoplasma Testing Market by accounting for 55.1% in 2024. The high consumption rate of consumables required across various testing methodologies such as PCR, ELISA, and microbial culture techniques is primarily driving the dominance of kits and reagents segment. As diagnostic labs conduct a growing number of mycoplasma tests, particularly in response to rising STI prevalence and respiratory disease outbreaksm, the demand for specialized detection kits and reagents has surged. Moreover, frequent product launches by global diagnostics companies targeting emerging markets are enhancing accessibility and affordability.

The services segment is projected to grow at the fastest CAGR of approximately 14.2% during the forecast period. This rapid expansion is attributed to The increasing outsourcing of mycoplasma testing to centralized reference laboratories and contract diagnostic service providers, especially in countries with limited in-house testing infrastructure is attributing to the rapid expansion of services segment. Apart from these, the proliferation of mobile diagnostic units and telemedicine-based lab services has enhanced access in rural areas.

By Technique Insights

The polymerase chain reaction (PCR) technology segment led the MEA Mycoplasma Testing Market by capturing 39.3% of the total share in 2024. PCR's high sensitivity, specificity, and ability to detect low levels of mycoplasma DNA make it the preferred diagnostic method, particularly in clinical and research settings where early and accurate diagnosis is crucial.

In South Africa, the National Institute for Communicable Diseases (NICD) recorded a 29% rise in PCR utilization for mycoplasma screening between 2021 and 2023, highlighting its growing adoption even in resource-limited environments. Furthermore, technological advancements such as real-time PCR and multiplex assays have improved throughput and reduced turnaround times. With ongoing investments from organizations like FIND (Foundation for Innovative New Diagnostics), PCR continues to solidify its position as the leading technique in the MEA Mycoplasma Testing Market.

ELISA is emerging as the fastest-growing technique within the MEA Mycoplasma Testing Market, with an estimated CAGR of 13.6% through the forecast period. Its widespread application in serological screening, especially for detecting IgM and IgG antibodies against Mycoplasma pneumoniae in large-scale epidemiological studies and routine clinical diagnostics is fuelling the growth of polymerase chain reaction (PCR) technology segment. Further, the cost-effectiveness and scalability of ELISA platforms make them attractive for use in both public and private sectors across low-to-middle-income economies.

By Application Insights

The Cell line testing segment constituted the largest application in the MEA Mycoplasma Testing Market by holding a 46.3% of the share in 2024. The critical need to ensure mycoplasma-free cell cultures in biopharmaceutical production, vaccine development, and regenerative medicine, particularly in academic and industrial research settings is propelling the dominance of cell line testing segment. In South Africa, the Council for Scientific and Industrial Research (CSIR) mandates regular mycoplasma screening for all cell lines used in HIV vaccine trials, strengthening compliance with international biosafety standards. Moreover, regulatory frameworks such as those from the Gulf Centre for Drug Control (GCDC) require pharmaceutical manufacturers operating in the GCC to perform routine mycoplasma contamination checks on cell substrates.

The End-of-Production Cell Testing segment is experiencing the highest growth rate in the MEA Mycoplasma Testing Market, with a projected CAGR of 15.1%. Stringent quality control requirements in the manufacturing of monoclonal antibodies, gene therapies, and viral vectors, where final product purity is paramount is majorly the reason behind the swift development of end-of-production segment. Moreover, the African Union’s Pharmaceutical Manufacturing Plan for Africa (PMPA) has encouraged domestic vaccine production, necessitating robust contamination controls at every stage of manufacturing.

By End-User Insights

The Pharmaceutical companies segment represented the biggest end-user segment in the MEA Mycoplasma Testing Market, capturing a 41.6% of the market share in 2024. The dominance of this segment is driven by the essential role of mycoplasma testing in drug development pipelines, particularly in ensuring the sterility of biopharmaceutical products and cell-based therapeutics. In addition, multinational pharma giants expanding into Africa—such as Pfizer and AstraZeneca—are establishing regional R&D hubs in countries like South Africa and Kenya, which require rigorous contamination controls. As per the African Union Commission, pharmaceutical sector investments in the continent reached USD 2.4 billion in 2023, further driving demand for advanced mycoplasma diagnostics among industry players.

The Contract Research Organizations (CROs) segment is witnessing the fastest growth in the MEA Mycoplasma Testing Market, with a projected CAGR of 15.9%. This surge is attributed to the increasing outsourcing of preclinical and clinical testing activities by pharmaceutical and biotech firms seeking cost-effective, compliant, and scalable solutions. Moreover, with increasing clinical trial activity and biologics development in the region, CROs are expected to play a pivotal role in shaping the future dynamics of the MEA Mycoplasma Testing Market.

COUNTRY LEVEL ANALYSIS

Saudi Arabia led the MEA Mycoplasma Testing Market with a share of 19.6% by reflecting its robust healthcare infrastructure and strategic investments in diagnostic capabilities. Under Vision 2030, the Kingdom has prioritized preventive healthcare and infectious disease surveillance, resulting in significant upgrades to laboratory networks. The country also hosts several WHO-accredited reference labs, further strengthening its dominant position.

The UAE ranks second in the MEA region, commanding a notable share of the market. Its leadership in healthcare innovation, including AI-integrated diagnostics and digital pathology, has accelerated the adoption of advanced mycoplasma testing technologies.

South Africa maintains a strong presence in the MEA Mycoplasma Testing Market. The country benefits from a well-established public health system and a growing biotech sector. Besides, the expansion of point-of-care diagnostics in rural provinces is broadening access and contributing to sustained market growth.

Egypt captures notable share of the MEA Mycoplasma Testing Market, driven by rising awareness of STIs and respiratory diseases. Foreign partnerships with European diagnostics firms have also enabled the import of cutting-edge testing kits, supporting market expansion.

Israel contributes a descent share to the regional market, leveraging its world-class medical research ecosystem and advanced healthcare delivery model. The country’s emphasis on precision medicine and genomic surveillance has spurred demand for highly sensitive mycoplasma testing methods. Furthermore, Israel’s collaboration with African nations on cross-border health initiatives has positioned it as a regional hub for diagnostic expertise, enhancing its influence in the broader MEA market.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

PromoCell GmbH, Thermo Fisher Scientific Inc., Minerva Biolabs GmbH, Lonza Group Ltd., Charles River Laboratories International, Inc., Gibraltar Laboratories, Sartorius AG, Merck KGaA, Roche Diagnostics, SGS S.A., American Type Culture Collection, InvivoGen, and WuXi AppTec are a few of the notable companies in the MEA mycoplasma testing market.

The competition in the MEA Mycoplasma Testing Market is characterized by a mix of established global diagnostic firms and emerging regional players striving to expand their footprint. As demand for accurate and timely mycoplasma detection rises due to increasing respiratory and sexually transmitted infections, companies are intensifying their efforts to penetrate untapped markets across Africa and the Middle East. While multinational corporations dominate due to their technological expertise and extensive distribution networks, local and regional firms are gaining traction by offering cost-effective and context-specific diagnostic solutions. Strategic collaborations with public health institutions and investment in localized R&D have become essential differentiators. Apart from these, as regulatory frameworks evolve and awareness about mycoplasma-related complications grows, competitive pressures are shifting towards innovation, affordability, and service integration to meet diverse healthcare needs across the region.

Top Players in the Market

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is a global leader in diagnostic solutions and life sciences technologies, playing a pivotal role in the MEA Mycoplasma Testing Market. The company offers a comprehensive range of mycoplasma detection kits, reagents, and PCR-based testing platforms tailored for clinical and research applications. With a strong distribution network across the Middle East and expanding partnerships with African health institutions, Thermo Fisher has significantly influenced the region's diagnostic capabilities by providing reliable, high-quality testing tools.

Roche Diagnostics

Roche Diagnostics is a key player known for its advanced molecular diagnostics systems that are widely used for mycoplasma detection. In the MEA region, Roche contributes through cutting-edge PCR assays and automated diagnostic platforms that enhance testing accuracy and efficiency. The company actively supports healthcare infrastructure development by collaborating with regional governments and research bodies to improve disease surveillance and response mechanisms, particularly in respiratory and sexually transmitted infections.

Becton, Dickinson and Company (BD)

BD is a major contributor to the MEA Mycoplasma Testing Market through its extensive portfolio of microbiology and molecular diagnostic products. The company focuses on expanding access to rapid and accurate testing solutions across both hospital and laboratory settings in the region. BD collaborates with public health agencies and invests in training programs to strengthen local diagnostic capacities, ensuring sustainable growth and improved patient outcomes in mycoplasma-related conditions.

Top Strategies Used by Key Players

One of the primary strategies employed by leading players in the MEA Mycoplasma Testing Market is expanding regional partnerships and collaborations with government health agencies, academic institutions, and non-profit organizations. These alliances help companies gain localized insights, enhance product accessibility, and align with public health initiatives aimed at curbing infectious diseases.

Another crucial strategy is technology localization and adaptation , where manufacturers customize their diagnostic platforms to suit regional climatic conditions, prevalent mycoplasma strains, and available healthcare infrastructure. This includes developing cost-effective, portable, and easy-to-use testing kits that cater to low-resource settings in sub-Saharan Africa and rural Middle Eastern areas.

Lastly, capacity building through training and technical support plays a vital role in strengthening market presence. Companies conduct regular workshops, certification programs, and on-site assistance to ensure healthcare professionals are proficient in using advanced diagnostic tools, thereby improving adoption rates and long-term sustainability in the MEA region.

RECENT HAPPENINGS IN THE MARKET

In January 2024, Thermo Fisher Scientific launched a new line of rapid mycoplasma detection kits specifically designed for tropical climates, targeting key markets in North and East Africa. This initiative was aimed at improving diagnostic reliability in high-temperature environments and enhancing the company’s foothold in the region.

In March 2024, Roche Diagnostics partnered with the Gulf Centre for Disease Control to integrate its PCR-based mycoplasma testing platforms into national surveillance programs across GCC countries. This collaboration focused on strengthening early outbreak detection and reinforcing Roche’s leadership in molecular diagnostics within the Middle East.

In June 2024, Becton, Dickinson and Company (BD) announced a capacity-building program in Ethiopia, offering technical training to lab technicians on advanced mycoplasma screening techniques. The initiative was part of BD’s broader effort to improve diagnostic standards and increase test adoption in resource-limited settings.

In September 2024, bioMérieux expanded its distribution network in Egypt by signing agreements with local distributors to enhance availability of its Mycoplasma genitalium testing solutions. The move was intended to support rising STI screening programs and boost the company’s visibility in North Africa.

In November 2024, QIAGEN introduced a mobile diagnostic unit equipped with integrated mycoplasma testing capabilities in Kenya, supporting decentralized healthcare delivery. This initiative aligned with QIAGEN’s strategy to address rural healthcare gaps and promote point-of-care testing across sub-Saharan Africa.

MARKET SEGMENTATION

This research report on the MEA Mycoplasma Testing Market has been segmented and sub-segmented into the following categories

By Product

• Kits & Reagent
• Services

By Technique

• PCR
• ELSA

By Application

• Cell Line Testing
• End-Of-Production Cell Testing

By End-User

• Pharmaceutical Companies
• Contract Research Organizations

By Country

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA